Literature DB >> 19340912

A combination treatment of entecavir and early-phase corticosteroid in severe exacerbation of chronic hepatitis B.

Kazuyuki Matsumoto1, Yasuhiro Miyake, Hirokazu Miyatake, Masahiro Takahara, Takayuki Imada, Satoru Yagi, Tatsuya Toyokawa, Morihito Nakatsu, Masaharu Ando, Mamoru Hirohata.   

Abstract

Of patients with severe exacerbation of chronic hepatitis B accompanied by jaundice and coagulopathy, 20%-30% have a fatal outcome. In this report, we describe 2 cases of severe exacerbation of chronic hepatitis B with jaundice and coagulopathy who were successfully treated with a combination of entecavir and corticosteroid. In both cases, rapid reductions in serum hepatitis B virus (HBV)-DNA levels were observed, and corticosteroid was stopped after serum HBV-DNA levels became undetectable. Entecavir treatment was continued. Generally, entecavir treatment reduced serum HBV-DNA levels rapidly, although the improvement in liver function was delayed by a few weeks. During this time lag, liver cell injury continued and the disease progressed. Corticosteroid suppressed the excessive host immune response and was useful for stopping progressive deterioration. A combination of entecavir and early-phase corticosteroid may be a useful treatment in severe exacerbation of chronic hepatitis B.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19340912      PMCID: PMC2669952          DOI: 10.3748/wjg.15.1650

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  16 in total

Review 1.  Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.

Authors:  R P Perrillo
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

2.  Prognostic factors in severe exacerbation of chronic hepatitis B.

Authors:  Man-Fung Yuen; Erwin Sablon; Chee-Kin Hui; Tak-Ming Li; He-Jun Yuan; Danny Ka-Ho Wong; Joke Doutreloigne; Veerle Bogaerts; Benjamin Chun-Yu Wong; Sheung-Tat Fan; Ching-Lung Lai
Journal:  Clin Infect Dis       Date:  2003-04-02       Impact factor: 9.079

3.  A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial.

Authors:  J H Hoofnagle; G L Davis; S C Pappas; R G Hanson; M Peters; M I Avigan; J G Waggoner; E A Jones; L B Seeff
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

Review 4.  Evolving concepts of the clinical and serologic consequences of hepatitis B virus infection.

Authors:  L B Seeff; R S Koff
Journal:  Semin Liver Dis       Date:  1986-02       Impact factor: 6.115

5.  A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy.

Authors:  M-F Yuen; H-J Yuan; C-K Hui; D K-H Wong; W-M Wong; A O-O Chan; B C-Y Wong; C-L Lai
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

6.  Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors:  Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis.

Authors:  K C Lam; C L Lai; C Trepo; P C Wu
Journal:  N Engl J Med       Date:  1981-02-12       Impact factor: 91.245

8.  Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B.

Authors:  G H Scullard; C I Smith; T C Merigan; W S Robinson; P B Gregory
Journal:  Gastroenterology       Date:  1981-12       Impact factor: 22.682

9.  Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells.

Authors:  C K Chou; L H Wang; H M Lin; C W Chi
Journal:  Hepatology       Date:  1992-07       Impact factor: 17.425

Review 10.  Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.

Authors:  George V Papatheodoridis; Spilios Manolakopoulos; Geoffrey Dusheiko; Athanasios J Archimandritis
Journal:  Lancet Infect Dis       Date:  2007-11-28       Impact factor: 25.071

View more
  5 in total

1.  The requirement for a sufficient period of corticosteroid treatment in combination with nucleoside analogue for severe acute exacerbation of chronic hepatitis B.

Authors:  Keiichi Fujiwara; Shin Yasui; Koichiro Okitsu; Yutaka Yonemitsu; Shigeto Oda; Osamu Yokosuka
Journal:  J Gastroenterol       Date:  2010-07-09       Impact factor: 7.527

2.  Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.

Authors:  Hui Zhang; Jianchun Xian; Yang Li; Li Xiao; Lu Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-30       Impact factor: 2.650

3.  Plasma Interleukin-10: A Likely Predictive Marker for Hepatitis B Virus-Related Acute-on-Chronic Liver Failure.

Authors:  Ke Wang; Zhe-Bin Wu; Yi-Nong Ye; Jing Liu; Geng-Lin Zhang; Yu-Jie Su; Hong-Liang He; Yu-Bao Zheng; Zhi-Liang Gao
Journal:  Hepat Mon       Date:  2014-07-14       Impact factor: 0.660

Review 4.  The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysis.

Authors:  Weiyan Yu; Caiyan Zhao; Chuan Shen; Yadong Wang; Hongzhi Lu; Jing Fan
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

Review 5.  Update on entecavir in the management of severe forms of Hepatitis B.

Authors:  Rodolfo Sacco
Journal:  Hepat Med       Date:  2012-05-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.